Closed · PA-07-451 · CFDA 93.242;93.273;93.371;93.837;93.853;93.859 · Discretionary
New Technology for Proteomics and Glycomics (SBIR [R43/R44])
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- -
- Close date
- -
- Expected awards
The verdict
New Technology for Proteomics and Glycomics (SBIR [R43/R44]) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.242;93.273;93.371;93.837;93.853;93.859
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
New Technology for Proteomics and Glycomics is closed. Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
This listing is no longer accepting applications
Instrument
Grant
Description
-Purpose. Proteomics technologies and methods remain largely inadequate, particularly with respect to quantitative and real time measurements. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-07-452, that solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. -Funds Available and Anticipated Number of Awards. For this funding opportunity, budgets up to $200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $400,000 total costs per year and up to 4 years may be requested for Phase II. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Market-open applicant set · includes for-profit door
The eligibility set for New Technology for Proteomics and Glycomics includes a for-profit door among 2 printed types (Small businesses; Others (see official listing text)). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Health (HL). Only 32 other National Institutes of Health listings share this exact eligibility-code string (0% of 12,420).
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
New Technology for Proteomics and Glycomics is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.242;93.273;93.371;93.837;93.853;93.859 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |